[ET Net News Agency, 23 July 2019] Jacobson Pharma Corporation Limited (02633) said its
subsidiary Sampan Development Limited (the purchaser) has agreed to buy 43% of the issued
share capital of Orizen Capital Limited (the target) at an aggregate consideration of
HK$113.38 million. Immediately after completion, the target will be held as to 88% by the
purchaser.
The target is principally engaged in the proprietary Chinese medicine business. The
acquisition represents a compelling opportunity to accelerate the group's strategy in
enhancing the portfolio of its proprietary medicine business. It lays the foundation to
create a leading branded Chinese medicine business which will be well-positioned to
deliver strong sales, cash-flow and earnings growth for the group. (RC)